Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model

QR Code

Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model

Systems pharmacology:Predicting efficacy of novel anti-cancer drugs in colorectal cancer While cancer drug development relies on experimental tumor models for testing, results observed in these systems often fail to translate clinically. Kirouac et al. demonstrate how computational systems modelling...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Daniel C. Kirouac, Gabriele Schaefer, Jocelyn Chan, Mark Merchant, Christine Orr, Shih-Min A. Huang, John Moffat, Lichuan Liu, Kapil Gadkar, Saroja Ramanujan
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2017
Sujets:	Biology (General) QH301-705.5
Accès en ligne:	https://doaj.org/article/6bfc02d0615b4d33ac88a7be2e3e419b
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
par: Shujun Han, et autres
Publié: (2018)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
par: Rengyun Liu, et autres
Publié: (2018)

Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
par: Shujun Han, et autres
Publié: (2018)

Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer
par: Keita Tanaka, et autres
Publié: (2021)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
par: Maurício Fernando Silva Almeida Ribeiro, et autres
Publié: (2021)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
par: Zaharie F, et autres
Publié: (2015)

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
par: Shujing Liu, et autres
Publié: (2018)

Mutant-selective degradation by BRAF-targeting PROTACs
par: Shanique Alabi, et autres
Publié: (2021)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
par: Hima Patel, et autres
Publié: (2021)

Author Correction: Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
par: Shujing Liu, et autres
Publié: (2019)

Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas.
par: Elena González-Sánchez, et autres
Publié: (2013)

Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules.
par: Jieun Koh, et autres
Publié: (2013)

The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors.
par: Ashwin A Dihal, et autres
Publié: (2013)

Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with <i>BRAF<sup>V600E</sup></i>-Mutant Advanced Papillary Thyroid Carcinoma
par: Eyun Song, et autres
Publié: (2021)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
par: Jennifer A. Silver, et autres
Publié: (2021)

BRAF Gene Mutation Analysis in Colorectal Cancer in South of Iran
par: Farshid Javadi, et autres
Publié: (2014)

Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma
par: Tang HC, et autres
Publié: (2015)

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
par: Qing Yin, et autres
Publié: (2019)

Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto’s Thyroiditis
par: Qin Zhang, et autres
Publié: (2017)

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
par: Matthew J. Sale, et autres
Publié: (2019)

Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency.
par: Megan C Hanna, et autres
Publié: (2013)

Machine learning algorithm improved automated droplet classification of ddPCR for detection of BRAF V600E in paraffin-embedded samples
par: Gabriel A. Colozza-Gama, et autres
Publié: (2021)

Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600 E/K mutated malignant melanomas
par: Sebastian Klein, et autres
Publié: (2021)

Author Correction: A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening
par: Jrhau Lung, et autres
Publié: (2021)

Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations
par: Raphaela Fritsche-Guenther, et autres
Publié: (2018)

PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
par: Gang Yang, et autres
Publié: (2021)

Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case
par: Tian Yang, et autres
Publié: (2021)

Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification
par: Sara Moreno, et autres
Publié: (2021)

Author Correction: Machine learning algorithm improved automated droplet classification of ddPCR for detection of BRAF V600E in paraffin-embedded samples
par: Gabriel A. Colozza-Gama, et autres
Publié: (2021)

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers
par: Yongxing Wu, et autres
Publié: (2021)

Melanoma Targeted Therapies beyond <i>BRAF</i>-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
par: Karam Khaddour, et autres
Publié: (2021)

Hole-in-one mutant phenotypes link EGFR/ERK signaling to epithelial tissue repair in Drosophila.
par: Jennifer A Geiger, et autres
Publié: (2011)

Acta Nº600
par: Banco Central de Chile
Publié: (2019)

Meet 600 HIGHWAYMEN
par: Emeline Jouve
Publié: (2021)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
par: Antoni Ribas, et autres
Publié: (2020)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
par: Wolfram Samlowski, et autres
Publié: (2021)

Clinicopathological Significance of BRAF (V600E), NRAS (Q61K) and TERT (C228T, C250T and SNP Rs2853669) Mutations in Bulgarian Papillary Thyroid Carcinoma Patients
par: Vidinov K., et autres
Publié: (2021)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
par: Maria Gonzalez-Cao, et autres
Publié: (2021)

Targeting ERK induced cell death and p53/ROS-dependent protective autophagy in colorectal cancer
par: Wunan Mi, et autres
Publié: (2021)

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
par: Najla Fakhruddin, et autres
Publié: (2017)